We are live on ! Find out more

Rapport Therapeutics

RAPP

Market cap $1.41B

29.37 USD

+0.77

2.69%

At close Updated Oct 20, 4:00 PM EDT

Pre-market

After hours

28.40

-0.97

3.3%

1 day

2.69%

5 days

2.3%

1 month

-25.95%

3 months

-26.96%

6 months

-20.92%

Year to date

4.48%

1 year

11.12%

5 years

41.2%

10 years

41.2%

About: Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Employees: 84

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 50%

Negative 7.1%

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcript

Why Is Rapport Therapeutics Stock Trading Higher Today?

Rapport Therapeutics Inc. (NASDAQ:RAPP) stock is trading higher on Tuesday with a premarket session volume of 1.439 million versus the average volume of 351.078 thousand, according to Benzinga Pro data.

Why Is Rapport Therapeutics Stock Trading Higher Today?

Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging

Positive trial data for Rapport's lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 billion peak sales opportunity, Jefferies says.

Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surging

Investors Business Daily

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher

Rapport Therapeutics stock shot higher Tuesday on promising, but mixed, test results for its bipolar treatment.

Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Shoots Higher

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024)

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade

Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 shows strong efficacy in focal onset seizures, with up to 90% median reduction in clinical seizures, supporting optimism for Phase 3 success. Analysts remain focused on the FOS opportunity, viewing the upcoming bipolar mania readout as potentially more instructive for safety than efficacy.

Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgrade

Investors Business Daily

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Biotech Stocks Dive As Top 2% Names Take Hardest Hit

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Zacks Investment Research

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday

See News Rankings

Price charts implemented using Lightweight Charts™